{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:23Z","timestamp":1790958683049,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T00:00:00Z","timestamp":1469059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/bjc.2016.215","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T22:50:48Z","timestamp":1469141448000},"page":"442-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer"],"prefix":"10.1038","volume":"115","author":[{"given":"N V","family":"Rajeshkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Yabuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta G","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihe","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,21]]},"reference":[{"issue":"4","key":"BFbjc2016215_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/bjc.2013.415","volume":"109","author":"R Alvarez","year":"2013","unstructured":"Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Munoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M (2013) Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109 (4): 926\u2013933.","journal-title":"Br J Cancer"},{"issue":"6024","key":"BFbjc2016215_CR2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (6024): 1612\u20131616.","journal-title":"Science"},{"issue":"7424","key":"BFbjc2016215_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N . Australian Pancreatic Cancer Genome I Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 (7424): 399\u2013405.","journal-title":"Nature"},{"issue":"6","key":"BFbjc2016215_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403\u20132413.","journal-title":"J Clin Oncol"},{"issue":"5","key":"BFbjc2016215_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CAD.0000000000000073","volume":"25","author":"EG Chiorean","year":"2014","unstructured":"Chiorean EG, Von Hoff DD (2014) Taxanes: impact on pancreatic cancer. Anticancer Drugs 25 (5): 584\u2013592.","journal-title":"Anticancer Drugs"},{"issue":"10","key":"BFbjc2016215_CR6","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","volume":"28","author":"G Colucci","year":"2010","unstructured":"Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolo M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia M Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato D, Gruppo Oncologico Italiano di Ricerca C (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28 (10): 1645\u20131651.","journal-title":"J Clin Oncol"},{"issue":"7451","key":"BFbjc2016215_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497 (7451): 633\u2013637.","journal-title":"Nature"},{"issue":"19","key":"BFbjc2016215_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of U, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817\u20131825.","journal-title":"N Engl J Med"},{"issue":"4","key":"BFbjc2016215_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 (4): 1317\u20131324.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc2016215_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2 (3): 260\u2013269.","journal-title":"Cancer Discov"},{"issue":"13","key":"BFbjc2016215_CR11","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14 (13): 4200\u20134205.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"BFbjc2016215_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","volume":"12","author":"I Garrido-Laguna","year":"2015","unstructured":"Garrido-Laguna I, Hidalgo M (2015) Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 12 (6): 319\u2013334.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"BFbjc2016215_CR13","doi-asserted-by":"publisher","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","volume":"107","author":"D Goldstein","year":"2015","unstructured":"Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD (2015) nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107 (2): dju413.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"BFbjc2016215_CR14","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27 (22): 3611\u20133619.","journal-title":"J Clin Oncol"},{"issue":"8","key":"BFbjc2016215_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","volume":"60","author":"MJ Hawkins","year":"2008","unstructured":"Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60 (8): 876\u2013885.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"BFbjc2016215_CR16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3748\/wjg.v18.i12.1286","volume":"18","author":"M Herreros-Villanueva","year":"2012","unstructured":"Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L (2012) Mouse models of pancreatic cancer. World J Gastroenterol 18 (12): 1286\u20131294.","journal-title":"World J Gastroenterol"},{"issue":"17","key":"BFbjc2016215_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362 (17): 1605\u20131617.","journal-title":"N Engl J Med"},{"issue":"8","key":"BFbjc2016215_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","volume":"10","author":"M Hidalgo","year":"2011","unstructured":"Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10 (8): 1311\u20131316.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"BFbjc2016215_CR19","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1158\/1078-0432.CCR-14-3222","volume":"21","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD (2015) SPARC expression did not predict efficacy of nab-Paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT Trial. Clin Cancer Res 21 (21): 4811\u20134818.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"BFbjc2016215_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrc3972","volume":"15","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM (2015) Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15 (8): 451\u2013452.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"BFbjc2016215_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/path.4651","volume":"238","author":"CI Hwang","year":"2016","unstructured":"Hwang CI, Boj SF, Clevers H, Tuveson DA (2016) Preclinical models of pancreatic ductal adenocarcinoma. J Pathol 238 (2): 197\u2013204.","journal-title":"J Pathol"},{"issue":"10","key":"BFbjc2016215_CR22","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1172\/JCI42754","volume":"121","author":"H Ijichi","year":"2011","unstructured":"Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121 (10): 4106\u20134117.","journal-title":"J Clin Invest"},{"issue":"5897","key":"BFbjc2016215_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (5897): 1801\u20131806.","journal-title":"Science"},{"issue":"1","key":"BFbjc2016215_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/path.4172","volume":"230","author":"R Kadaba","year":"2013","unstructured":"Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, Soylu E, Ghallab M, Bor D, Froeling FE, Bhattacharya S, Rustgi AK, Sahai E, Chelala C, Sasieni P, Kocher HM (2013) Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol 230 (1): 107\u2013117.","journal-title":"J Pathol"},{"issue":"3","key":"BFbjc2016215_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/0008-5472.CAN-14-2211","volume":"75","author":"JJ Kamphorst","year":"2015","unstructured":"Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD (2015) Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 75 (3): 544\u2013553.","journal-title":"Cancer Res"},{"issue":"11","key":"BFbjc2016215_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/nprot.2009.171","volume":"4","author":"MP Kim","year":"2009","unstructured":"Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4 (11): 1670\u20131680.","journal-title":"Nat Protoc"},{"issue":"28","key":"BFbjc2016215_CR27","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1200\/JCO.2011.37.3464","volume":"29","author":"AH Ko","year":"2011","unstructured":"Ko AH (2011) FOLFIRINOX: a small step or a great leap forward? J Clin Oncol 29 (28): 3727\u20133729.","journal-title":"J Clin Oncol"},{"issue":"20","key":"BFbjc2016215_CR28","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-13-1356","volume":"19","author":"WW MA","year":"2013","unstructured":"MA WW, Hidalgo M (2013) The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 19 (20): 5572\u20135579.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2016215_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","volume":"3","author":"A Maitra","year":"2008","unstructured":"Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157\u2013188.","journal-title":"Annu Rev Pathol"},{"issue":"12 Suppl","key":"BFbjc2016215_CR30","doi-asserted-by":"publisher","first-page":"C246","DOI":"10.1158\/1535-7163.TARG-09-C246","volume":"8","author":"A Maitra","year":"2009","unstructured":"Maitra A, Rajeshkumar NV, Rudek M, Garrido-Laguna I, Laheru D, Iglesias J, Desai N, Von Hoff D, Hidalgo M (2009) nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models. Mol Cancer Ther 8 (12 Suppl): C246.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"BFbjc2016215_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1179\/joc.2011.23.2.59","volume":"23","author":"M Montana","year":"2011","unstructured":"Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P (2011) Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers. J Chemother 23 (2): 59\u201366.","journal-title":"J Chemother"},{"issue":"6","key":"BFbjc2016215_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/gutjnl-2013-305559","volume":"63","author":"A Neesse","year":"2014","unstructured":"Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA (2014) SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63 (6): 974\u2013983.","journal-title":"Gut"},{"issue":"9","key":"BFbjc2016215_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ctrv.2014.07.003","volume":"40","author":"H Oettle","year":"2014","unstructured":"Oettle H (2014) Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev 40 (9): 1039\u20131047.","journal-title":"Cancer Treat Rev"},{"issue":"22","key":"BFbjc2016215_CR34","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","volume":"28","author":"PA Philip","year":"2010","unstructured":"Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28 (22): 3605\u20133610.","journal-title":"J Clin Oncol"},{"issue":"3","key":"BFbjc2016215_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21 (3): 418\u2013429.","journal-title":"Cancer Cell"},{"issue":"9","key":"BFbjc2016215_CR36","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M (2011) MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 17 (9): 2799\u20132806.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"BFbjc2016215_CR37","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1158\/0008-5472.CAN-15-0108","volume":"75","author":"NV Rajeshkumar","year":"2015","unstructured":"Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, Dang CV, Gillies RJ, Maitra A (2015) Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res 75 (16): 3355\u20133364.","journal-title":"Cancer Res"},{"issue":"15","key":"BFbjc2016215_CR38","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-06-0113","volume":"12","author":"B Rubio-Viqueira","year":"2006","unstructured":"Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12 (15): 4652\u20134661.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BFbjc2016215_CR39","first-page":"2905","volume":"30","author":"MW Saif","year":"2010","unstructured":"Saif MW, Syrigos K, Penney R, Kaley K (2010) Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 30 (7): 2905\u20132909.","journal-title":"Anticancer Res"},{"issue":"11","key":"BFbjc2016215_CR40","first-page":"6609","volume":"34","author":"A Schneeweiss","year":"2014","unstructured":"Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A, Zorn M, Sinn HP, Marme F (2014) Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res 34 (11): 6609\u20136615.","journal-title":"Anticancer Res"},{"issue":"13","key":"BFbjc2016215_CR41","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27 (13): 2231\u20132237.","journal-title":"J Clin Oncol"},{"issue":"1","key":"BFbjc2016215_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-10-0893","volume":"10","author":"MC Villarroel","year":"2011","unstructured":"Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10 (1): 3\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"BFbjc2016215_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.critrevonc.2014.06.001","volume":"92","author":"A Viudez","year":"2014","unstructured":"Viudez A, Ramirez N, Hernandez-Garcia I, Carvalho FL, Vera R, Hidalgo M (2014) Nab-paclitaxel: a flattering facelift. Crit Rev Oncol Hematol 92 (3): 166\u2013180.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4 Suppl 13","key":"BFbjc2016215_CR44","first-page":"S13","volume":"24","author":"DD Von Hoff","year":"1997","unstructured":"Von Hoff DD (1997) The taxoids: same roots, different drugs. Semin Oncol 24 (4 Suppl 13): S13\u20133-S13-10.","journal-title":"Semin Oncol"},{"issue":"18","key":"BFbjc2016215_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18): 1691\u20131703.","journal-title":"N Engl J Med"},{"issue":"34","key":"BFbjc2016215_CR46","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 29 (34): 4548\u20134554.","journal-title":"J Clin Oncol"},{"issue":"1\u20132","key":"BFbjc2016215_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1615\/CritRevOncog.v18.i1-2.80","volume":"18","author":"C Whatcott","year":"2013","unstructured":"Whatcott C, Han H, Posner RG, Von Hoff DD (2013) Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog 18 (1\u20132): 135\u2013151.","journal-title":"Crit Rev Oncog"},{"issue":"15","key":"BFbjc2016215_CR48","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H (2015) Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 21 (15): 3561\u20133568.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"BFbjc2016215_CR49","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/caac.21190","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63 (5): 318\u2013348.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"BFbjc2016215_CR50","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA Committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102 (11): 1555\u20131577.","journal-title":"Br J Cancer"},{"issue":"2","key":"BFbjc2016215_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.gendis.2015.01.002","volume":"2","author":"D Xie","year":"2015","unstructured":"Xie D, Xie K (2015) Pancreatic cancer stromal biology and therapy. Genes Dis 2 (2): 133\u2013143.","journal-title":"Genes Dis"},{"issue":"1","key":"BFbjc2016215_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2013.01.054","volume":"335","author":"S Yabuuchi","year":"2013","unstructured":"Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV (2013) Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335 (1): 41\u201351.","journal-title":"Cancer Lett"},{"key":"BFbjc2016215_CR53","first-page":"371","volume":"6","author":"JA Yared","year":"2012","unstructured":"Yared JA, Tkaczuk KH (2012) Update on taxane development: new analogs and new formulations. Drug Des Dev Ther 6: 371\u2013384.","journal-title":"Drug Des Dev Ther"},{"issue":"21","key":"BFbjc2016215_CR54","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1158\/1078-0432.CCR-13-1485","volume":"19","author":"L Zhang","year":"2013","unstructured":"Zhang L, Marrano P, Kumar S, Leadley M, Elias E, Thorner P, Baruchel S (2013) Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res 19 (21): 5972\u20135983.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016215","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:33:13Z","timestamp":1684416793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,21]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFbjc2016215"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.215","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,21]]},"assertion":[{"value":"15 June 2016","order":1,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZT, SH, SB, DWP and CH are employees of Celgene Corporation. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}